Kindred Biosciences (KIN) Lowered to “Strong Sell” at BidaskClub

BidaskClub lowered shares of Kindred Biosciences (NASDAQ:KIN) from a sell rating to a strong sell rating in a research note released on Thursday, BidAskClub reports.

Several other equities analysts also recently commented on the stock. HC Wainwright reissued a buy rating and set a $19.00 target price on shares of Kindred Biosciences in a research report on Monday, January 14th. Cantor Fitzgerald set a $25.00 target price on shares of Kindred Biosciences and gave the stock a buy rating in a research report on Monday, January 14th. ValuEngine downgraded shares of Kindred Biosciences from a strong-buy rating to a buy rating in a research report on Thursday, April 11th. Lake Street Capital lowered their target price on shares of Kindred Biosciences from $30.00 to $12.00 and set a buy rating on the stock in a research report on Thursday, March 7th. Finally, Zacks Investment Research downgraded shares of Kindred Biosciences from a hold rating to a sell rating in a research report on Friday, January 18th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. Kindred Biosciences has a consensus rating of Buy and a consensus target price of $17.82.

NASDAQ KIN opened at $8.74 on Thursday. Kindred Biosciences has a 1-year low of $8.04 and a 1-year high of $15.75.

Kindred Biosciences (NASDAQ:KIN) last posted its earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.04). The business had revenue of $1.33 million for the quarter, compared to analysts’ expectations of $1.44 million. Research analysts forecast that Kindred Biosciences will post -1.54 EPS for the current year.

A number of institutional investors have recently bought and sold shares of KIN. Legal & General Group Plc grew its position in shares of Kindred Biosciences by 24.6% in the third quarter. Legal & General Group Plc now owns 4,659 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 920 shares during the last quarter. Metropolitan Life Insurance Co. NY grew its position in shares of Kindred Biosciences by 362.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 9,647 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 7,563 shares during the last quarter. Meeder Asset Management Inc. grew its position in shares of Kindred Biosciences by 17.5% in the fourth quarter. Meeder Asset Management Inc. now owns 10,216 shares of the biopharmaceutical company’s stock valued at $111,000 after purchasing an additional 1,518 shares during the last quarter. Grassi Investment Management acquired a new stake in shares of Kindred Biosciences in the fourth quarter valued at about $126,000. Finally, Teton Advisors Inc. acquired a new stake in shares of Kindred Biosciences in the fourth quarter valued at about $142,000. 56.83% of the stock is currently owned by hedge funds and other institutional investors.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Further Reading: Support Level

Analyst Recommendations for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.